RecallDepth
Class II Ongoing

Ranitidine Tablets, USP 300 mg, 250-count bottles, NDC 53746-254-02.

Company
Amneal Pharmaceuticals, Inc.
Recall Initiated
November 22, 2019
Posted
December 18, 2019
Recall Number
D-0616-2020
Voluntary / Mandated
Voluntary: Firm initiated
Firm Location
Brookhaven, NY, United States

Reason for Recall

CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Distribution

Product was distributed throughout the United States.

Lot / Code Info

HB04118A 2/2020 HB04218A 2/2020 HB04318A 2/2020 HB04418A 2/2020 HF13518A 6/2020 HF13618A 6/2020 HF13718A 6/2020 HF13818A 6/2020 HK02818A 9/2020 HK02918A 9/2020 HK03018A 9/2020 HK03118A 9/2020 HL08418A 11/2020 HL08518A 11/2020 HL08618A 11/2020 HL08718A 11/2020 HB01419A 1/2021 HB05619A 1/2021 HB05719A 1/2021 HB05819A 1/2021 HB05919A 1/2021 HB06019A 1/2021 HB06119A 1/2021

More recalls by Amneal Pharmaceuticals, Inc.

View all recalls by this company →

Other recent Class II Drug recalls